Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

NCT00456846 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00456846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00456846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Terminated
Start date
February 1, 2008
Completion date
May 31, 2013
Enrollment
123 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer